ARID1A and gastric carcinoma: Another study, encompassing 857 gastric carcinoma cases, including 67 EBV‐positive and 136 MLH1‐depleted cases (corresponding to the MSI‐high phenotype), identified frequent loss of ARID1A expression in EBV‐positive (34%) and MLH1‐deleted (29%) gastric carcinomas.